Mouse Vitiligo Models

Vitiligo is an autoimmune skin disorder characterized by patchy loss of skin color due to the destruction of melanocytes, often associated with CD8+ T cells specific for melanocyte differentiation antigens. HKeyBio offers a well-validated B16F10 cell induced vitiligo model in C57BL/6 mice. This model relies on transient inoculation of B16F10 melanoma cells combined with depletion of CD4+ regulatory T cells, which activates endogenous autoreactive CD8+ T cells to target epidermal melanocytes. The model recapitulates all key hallmarks of human vitiligo at phenotypic, histological, and signaling levels, including progressive depigmentation, CD8+ T cell infiltration in skin, and melanocyte loss. It provides a robust platform for preclinical efficacy testing of novel vitiligo therapeutics.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Clinically relevant – Recapitulates human vitiligo: CD8+ T cell mediated melanocyte destruction, progressive depigmentation, and skin pathology.

Immunological mechanism – Autoreactive CD8+ T cell activation against melanocyte antigens, with CD4+ Treg depletion.

Comprehensive endpoints – Body weight, spleen index, clinical score, CD8+ T cell levels in blood and skin, incidence rate, hair coat and tail skin pictures, histopathology, melanin-containing cell counts.

Translational value – Ideal for testing JAK inhibitors, topical immunomodulators, and biologics targeting T cell responses.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

C57BL/6 Vitiligo Model

2526322b48da628f878ef8bd5a4345f0

Applications

• Efficacy testing of JAK inhibitors (ruxolitinib, tofacitinib), topical immunomodulators, and biologics targeting CD8+ T cells

• Target validation for melanocyte-specific immune pathways

• Biomarker discovery (CD8+ T cell markers, melanocyte antigens)

• Mechanism of action (MOA) studies for autoimmune skin disorders

• IND-enabling pharmacology studies

Model Specifications

Parameter	Specificatio
Species/Strain	C57BL/6 mouse
Induction method	Subcutaneous inoculation of B16F10 melanoma cells + CD4+ T cell depletion (anti-CD4 antibody)
Study duration	4–8 weeks
Key endpoints	Body weight, spleen index, clinical score, CD8+ T cell levels in blood and skin (flow cytometry), incidence rate, hair and tail skin depigmentation scoring, skin histopathology (H&E, melanocyte staining), melanin-containing cell counts
Data package	Raw data, analysis reports, flow cytometry files, clinical photographs, histology slides, bioinformatics (optional)Raw data, analysis reports, glucose curves, histology slides, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What vitiligo preclinical model do you provide?

A1: We offer the B16F10 cell-induced vitiligo model using C57BL/6 mice for vitiligo-related preclinical studies and drug development.

Q2: What is the modeling mechanism?

A2: The model is established via B16F10 cell inoculation and CD4+ regulatory T cell depletion. It activates autoreactive CD8+ T cells to attack epidermal melanocytes, fully recapitulating the pathological features of human vitiligo.

Q3: What evaluation indicators are used?

A3: We monitor body weight and spleen index clinically, detect CD8+ T cell levels in blood and skin, and perform skin histopathological analysis.

Q4: What is the modeling process and cycle?

A4: B16F10 cells and anti-CD4 antibody are administered on Day 0, followed by tumor removal. The whole experiment ends on Day 84.

Q5: What are the advantages and application scenarios?

A5: This model presents stable and typical vitiligo phenotypes. It is a reliable platform for efficacy screening, mechanism research and preclinical assessment of anti-vitiligo drugs.